Unknown

Dataset Information

0

Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans.


ABSTRACT: With the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals for Zolgensma, Luxturna, and Glybera, recombinant adeno-associated viruses (rAAVs) are considered efficient tools for gene transfer. However, studies in animals and humans demonstrate that intramuscular (IM) AAV delivery can trigger immune responses to AAV capsids and/or transgenes. IM delivery of rAAV1 in humans has also been described to induce tolerance to rAAV characterized by the presence of capsid-specific regulatory T cells (Tregs) in periphery. To understand mechanisms responsible for tolerance and parameters involved, we tested 3 muscle-directed administration routes in rhesus monkeys: IM delivery, venous limb perfusion, and the intra-arterial push and dwell method. These 3 methods were well tolerated and led to transgene expression. Interestingly, gene transfer in muscle led to Tregs and exhausted T cell infiltrates in situ at both day 21 and day 60 post-injection. In human samples, an in-depth analysis of the functionality of these cells demonstrates that capsid-specific exhausted T cells are detected after at least 5 years post-vector delivery and that the exhaustion can be reversed by blocking the checkpoint pathway. Overall, our study shows that persisting transgene expression after gene transfer in muscle is mediated by Tregs and exhausted T cells.

SUBMITTER: Gernoux G 

PROVIDER: S-EPMC7054721 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans.

Gernoux Gwladys G   Gruntman Alisha M AM   Blackwood Meghan M   Zieger Marina M   Flotte Terence R TR   Mueller Christian C  

Molecular therapy : the journal of the American Society of Gene Therapy 20200113 3


With the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals for Zolgensma, Luxturna, and Glybera, recombinant adeno-associated viruses (rAAVs) are considered efficient tools for gene transfer. However, studies in animals and humans demonstrate that intramuscular (IM) AAV delivery can trigger immune responses to AAV capsids and/or transgenes. IM delivery of rAAV1 in humans has also been described to induce tolerance to rAAV characterized by the presence of capsid-  ...[more]

Similar Datasets

| S-EPMC6330508 | biostudies-literature
| S-EPMC10503678 | biostudies-literature
| S-EPMC3222540 | biostudies-literature
| S-EPMC10115413 | biostudies-literature
| S-EPMC5984508 | biostudies-literature
| S-EPMC6249602 | biostudies-literature
| S-EPMC6936571 | biostudies-literature
| S-EPMC8223552 | biostudies-literature
| S-EPMC2852878 | biostudies-literature
| S-EPMC7978427 | biostudies-literature